V1 sact_regimen
730,471 rows · 12 columns
| MERGED_REGIMEN_ID | MERGED_TUMOUR_ID | HEIGHT_AT_START_OF_REGIMEN | WEIGHT_AT_START_OF_REGIMEN | INTENT_OF_TREATMENT | DATE_DECISION_TO_TREAT | START_DATE_OF_REGIMEN | MAPPED_REGIMEN | CLINICAL_TRIAL | CHEMO_RADIATION | MERGED_PATIENT_ID | BENCHMARK_GROUP |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 210033705 | 210013922 | 1.68 | 71.4 | null | 2015-06-30 | 2015-09-30 | Carboplatin + Paclitaxel (weekly) | N | null | 210034650 | LIPOSOMAL CYTARABINE |
| 210033706 | 210013924 | 1.77 | 50.35 | Curative (C) | 2018-07-16 | 2018-07-22 | DOXORUBICIN | N | N | 210034878 | CYTARABINE |
| 210033707 | 210013927 | 1.69 | 19.75 | Curative (C) | 2016-02-07 | 2016-05-10 | Cyclophosphamide High Dose | 02 | N | 210035018 | UKALL2003 |
| 210033708 | 210013930 | 1.75 | 78 | Disease modification (D) | 2018-06-11 | 2018-06-11 | MERCAPTOPURINE + METHOTREXATE + VINCRISTINE | N | N | 210035201 | CARBO + ETOPOSIDE + VINCRISTINE |
| 210033709 | 210022694 | 1.62 | 61.8 | Palliative (P) | null | 2019-09-16 | CISPLATIN + ETOPOSIDE | Y | null | 210035396 | DAUNORUBICIN + VNCRISTINE |
| 210033710 | 210033722 | null | 76.1 | Curative (C) | 2016-12-13 | 2017-08-07 | PACLITAXEL | N | N | 210035468 | CLL210 TRIAL |
| 210033711 | 210013939 | 1.77 | 10.7 | Curative (C) | 2016-12-26 | 2017-01-06 | GEM-P | 2 | N | 210035520 | TRASTUZUMAB |
| 210033712 | 210022697 | 1.75 | 60.6 | Curative (C) | 2016-01-23 | 2016-07-26 | CNS LGG Irinotecan & Bevacizumab | N | N | 210035533 | DOCETAXEL |
| 210033713 | 210013952 | null | 47.9 | Curative (C) | 2017-10-12 | 2017-11-11 | Maintenance Therapy ALL | null | N | 210036454 | NILOTINIB |
| 210033714 | 210013956 | 1.91 | 91.2 | Curative (C) | 2015-02-12 | 2015-02-16 | IVAC | 2 | N | 210036485 | CLL210 TRIAL |
| 210033715 | 210022706 | 1.73 | 79.2 | Adjuvant (A) | 2020-03-31 | 2020-03-31 | Bortezomib + CYCLOPHOSPHAMIDE | 2 | N | 210036496 | MPT |
| 210033716 | 210013961 | 1.71 | 94 | Disease modification (D) | 2019-10-25 | 2019-10-25 | PACLITAXEL | N | N | 210036578 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210033717 | 210013964 | 1.59 | 47 | Curative (C) | null | 2015-11-16 | Cytarabine Intrathecal (any age) | 2 | N | 210036643 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE |
| 210033718 | 210022719 | 1.72 | 39.2 | Curative (C) | 2019-05-30 | 2019-06-07 | CYCLOPHOSPHAMIDE + ETOPOSIDE + VINCRISTINE | N | N | 210037672 | CLL210 TRIAL |
| 210033719 | 210013981 | null | 53.5 | Disease modification (D) | 2020-02-22 | 2020-03-21 | Obinutuzumab | N | null | 210037675 | CYTARABINE INTRATHECAL |
| 210033720 | 210013988 | 1.82 | 26.8 | Adjuvant (A) | 2018-02-24 | 2018-03-10 | CLARITY Trial | N | N | 210038079 | MITOMYCIN INTRAVESICULAR |
| 210033721 | 210013995 | 0 | 70.8 | Curative (C) | null | 2018-09-08 | Clofarabine + Cytarabine | N | N | 210038641 | IVE-R |
| 210033722 | 210022733 | 1.65 | null | Curative (C) | 2014-11-17 | 2015-01-28 | DACTINOMYCIN + CYCLO + VINCRISTINE | N | Y | 210039506 | CODOX M |
| 210033723 | 210037469 | null | 71.4 | Disease modification (D) | 2017-06-29 | 2017-09-13 | IPILIMUMAB + NIVOLUMAB | 02 | null | 210039555 | ICE-R |
| 210033724 | 210014010 | 1.76 | 63 | Palliative (P) | 2016-06-20 | 2016-10-12 | Mitomycin Intravesical | null | N | 210039663 | UKALL2003 |
| 210033725 | 210014014 | 1.64 | null | Curative (C) | 2017-09-29 | 2017-11-11 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210040040 | BEAM |
| 210033726 | 210014025 | 1.7 | null | Curative (C) | null | 2018-03-27 | CARBOPLATIN + VINORELBINE | Y | N | 210040409 | UKALL 60+ TRIAL |
| 210033727 | 210022742 | null | 59.2 | Disease modification (D) | 2017-12-25 | 2017-12-25 | CLL210 TRIAL | N | null | 210041159 | ABVD |
| 210033728 | 210014041 | 1.86 | 69.9 | Neo-adjuvant (N) | 2017-03-25 | 2017-04-01 | Irinotecan + Modified De Gramont | N | N | 210041453 | UKALL2003 |
| 210033729 | 210022748 | null | 92 | Disease modification (D) | 2018-09-13 | 2019-09-23 | PNET 4 HIT-SIOP Maintenance | null | N | 210041755 | TAVAREC TRIAL |
| 210033730 | 210028266 | 1.6 | 47 | Disease modification (D) | 2019-01-11 | 2019-01-16 | Alemtuzumab + Cyclophos TBI Allo | N | N | 210041781 | CLL210 TRIAL |
| 210033731 | 210031617 | 1.64 | null | Curative (C) | 2016-10-11 | 2017-04-12 | LENVATINIB | N | N | 210042046 | ALL MAINTENANCE |
| 210033732 | 210014057 | 1.84 | 63.8 | Disease modification (D) | 2015-06-25 | 2016-03-29 | CARBO + ETOPOSIDE + VINCRISTINE | N | Y | 210042047 | CISPLATIN + ETOPOSIDE |
| 210033733 | 210022762 | 1.75 | 89 | null | 2015-10-02 | 2018-05-19 | BR14 TRIAL | N | N | 210024514 | ALEMTUZUMAB + CYCLOPHOSPHAMIDE + METHOTREXATE |
| 210033734 | 210014071 | null | 85.6 | Disease modification (D) | 2019-06-22 | 2019-09-21 | Cytarabine intrathecal | N | N | 210030920 | CYCLOPHOSPHAMIDE HIGH DOSE |
| 210033735 | 210028274 | 1.81 | 78.5 | Curative (C) | 2017-09-29 | 2017-10-06 | Bortezomib + Cyclophos + Dex | 02 | N | 210034307 | CYCLOPHOSPHAMIDE + ETOPOSIDE + NELARABINE |
| 210033736 | 210014086 | 1.62 | 34 | Palliative (P) | 2017-12-28 | 2017-12-28 | CYTARABINE + ETOPOSIDE | 2 | null | 210039936 | ALL MAINTENANCE |
| 210033737 | 210022777 | 1.72 | 38 | Palliative (P) | null | 2019-06-03 | Panitumumab | null | N | 210041640 | CLL210 TRIAL |
| 210033738 | 210014093 | 1.53 | 75.3 | Palliative (P) | 2020-01-30 | 2020-01-30 | Ibrutinib + Rituximab | N | N | 210013365 | DAUNORUBICIN + VNCRISTINE |
| 210033740 | 210032406 | 1.65 | 56.5 | Palliative (P) | 2016-04-10 | 2016-04-16 | Temozolomide 200mg/m2 | N | N | 210000163 | TEMOZOLOMIDE |
| 210033741 | 210004326 | null | 59 | Adjuvant (A) | 2014-10-08 | 2015-04-08 | TEMOZOLOMIDE | 2 | N | 210000208 | TEMOZOLOMIDE |
| 210033742 | 210004339 | 1.64 | null | Adjuvant (A) | 2016-05-27 | 2016-06-03 | Temozolomide 200mg/m2 | N | N | 210000223 | TEMOZOLOMIDE |
| 210033743 | 210004346 | 1.78 | 55.6 | Adjuvant (A) | 2014-04-14 | 2014-06-04 | TEMOZOLOMIDE | 02 | N | 210000265 | TEMOZOLOMIDE |
| 210033744 | 210017255 | 1.55 | 92.4 | Disease modification (D) | 2018-03-09 | 2018-03-31 | Temozolomide 150mg/m2 | 02 | N | 210000286 | TEMOZOLOMIDE |
| 210033745 | 210024691 | 1.81 | 0 | Adjuvant (A) | 2017-06-05 | 2018-03-13 | Temozolomide 200mg/m2 | N | N | 210000362 | TEMOZOLOMIDE |
| 210033746 | 210032416 | 1.72 | 77.5 | Palliative (P) | 2015-10-23 | 2015-10-25 | Temozolomide 200mg/m2 | N | N | 210000395 | TEMOZOLOMIDE |
| 210033747 | 210032417 | null | 69.4 | Adjuvant (A) | 2017-07-07 | 2017-07-07 | TEMOZOLOMIDE | 2 | N | 210000398 | TEMOZOLOMIDE |
| 210033748 | 210032421 | 1.74 | null | Palliative (P) | 2017-04-06 | 2017-07-18 | TEMOZOLOMIDE | 02 | N | 210000497 | TEMOZOLOMIDE |
| 210033749 | 210004400 | 1.75 | 98 | Adjuvant (A) | 2013-11-28 | 2014-04-15 | TEMOZOLOMIDE | 02 | null | 210000561 | TEMOZOLOMIDE |
| 210033750 | 210004403 | 1.67 | 80.1 | Adjuvant (A) | 2017-12-27 | 2018-05-03 | Temozolomide 200mg/m2 | 2 | N | 210000562 | TEMOZOLOMIDE |
| 210033751 | 210004406 | 1.78 | 96 | Adjuvant (A) | 2016-10-19 | 2016-10-21 | Temozolomide 200mg/m2 | N | N | 210000602 | TEMOZOLOMIDE |
| 210033752 | 210038311 | 1.89 | 133 | Curative (C) | 2016-11-19 | 2017-02-18 | TEMOZOLOMIDE | 02 | N | 210000612 | TEMOZOLOMIDE |
| 210033753 | 210004408 | 1.75 | null | Palliative (P) | 2013-11-21 | 2016-02-12 | TEMOZOLOMIDE | 2 | N | 210000663 | TEMOZOLOMIDE |
| 210033754 | 210004412 | 1.69 | null | Adjuvant (A) | 2018-03-11 | 2018-03-11 | Temozolomide 200mg/m2 | 02 | N | 210000691 | TEMOZOLOMIDE |
| 210033755 | 210024722 | 1.65 | 96 | Palliative (P) | null | 2017-02-04 | Temozolomide 200mg/m2 | N | N | 210000818 | TEMOZOLOMIDE |